Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells

被引:27
作者
Zhang, Shi-Neng [1 ]
Huang, Feng-Ting [1 ]
Huang, Yi-Jun [2 ]
Zhong, Wa [1 ]
Yu, Zhong [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 2, Dept Gastroenterol, Guangzhou 510120, Peoples R China
[2] Sun Yat Sen Univ Sci Med, Dept Pharmacol, Guangzhou, Guangdong, Peoples R China
来源
TUMORI JOURNAL | 2010年 / 96卷 / 06期
关键词
cancer stem cell; pancreatic adenocarcinoma; side population cells; DRUG EFFLUX CAPACITY; PROSPECTIVE IDENTIFICATION; ABCG2; RESISTANCE; HOECHST-33342; TRANSPORTER; PROPAGATION; RENEWAL; TISSUE;
D O I
10.1177/548.6520
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background. To identify and partially characterize the side population cells derived from three human pancreatic adenocarcinoma cell lines. Methods. Side population cells were sorted from the human pancreatic adenocarcinoma cell lines SW1990, Capan-2, and BxPC-3 using flow cytometry and then analyzed for cell proliferation, clone formation, differentiation, chemoresistance, invasive potential, and tumorigenicity in a mouse model. Results. Human pancreatic carcinoma cell lines SW1990, Capan-2, and BxPC-3 contain 2.7% +/- 0.35%, 3.6% +/- 1.2%, and 2.8% +/- 0.8% side population cells, respectively. We further investigated cancer stem cell characteristics with the moderately differentiated human pancreatic adenocarcinoma cell line SW1990. Flow cytometry analysis revealed that side population cells could differentiate into side population and non-side population cells and could exhibit differentiation potential. Using a clone formation assay, side population cells were shown to have a higher proliferation than non-side population cells. Compared to non-side population cells, side population cells were also more resistant to gemcitabine, a commonly used anti-cancer agent against pancreatic carcinoma, and were more invasive. Importantly, the CD 133 level in side population cells was significantly higher than that in non-side population cells. The enhanced tumorigenecity was further confirmed in a male diabetic/severe combined immunodeficiency mouse model. As few as 3 x 10(3) side population cells were sufficient to induce tumor formation in the mouse model, compared to 10(7) non-side population or unsorted cells. Conclusions. Side population cells isolated from human pancreatic adenocarcinoma cell lines harbor cancer stem cell-like properties that may be related to the invasive potential and therapeutic-resistance of pancreatic adenocarcinoma. Free full text available at www.tumorionline.it
引用
收藏
页码:985 / 992
页数:8
相关论文
共 37 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]  
[Anonymous], 2008, Cancer Facts Figures 2008
[3]   Tissue repair and stem cell renewal in carcinogenesis [J].
Beachy, PA ;
Karhadkar, SS ;
Berman, DM .
NATURE, 2004, 432 (7015) :324-331
[4]   ABC transporters as phenotypic markers and functional regulators of stem cells [J].
Bunting, KD .
STEM CELLS, 2002, 20 (01) :11-20
[5]   Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].
Burger, H ;
van Tol, H ;
Boersma, AWM ;
Brok, M ;
Wiemer, EAC ;
Stoler, G ;
Nooter, K .
BLOOD, 2004, 104 (09) :2940-2942
[6]   A side order of stem cells: The SP phenotype [J].
Challen, GA ;
Little, MH .
STEM CELLS, 2006, 24 (01) :3-12
[7]  
Chen ZS, 2003, CANCER RES, V63, P4048
[8]   Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties [J].
Chiba, Tetsuhiro ;
Kita, Kaoru ;
Zheng, Yun-Wen ;
Yokosuka, Osamu ;
Saisho, Hiromitsu ;
Iwama, Atsushi ;
Nakauchi, Hiromitsu ;
Taniguchi, Hideki .
HEPATOLOGY, 2006, 44 (01) :240-251
[9]   Prospective identification of tumorigenic prostate cancer stem cells [J].
Collins, AT ;
Berry, PA ;
Hyde, C ;
Stower, MJ ;
Maitland, NJ .
CANCER RESEARCH, 2005, 65 (23) :10946-10951
[10]  
Dou J, 2007, CELL MOL IMMUNOL, V4, P467